Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression
- 17 January 2012
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 109 (5), 1643-1648
- https://doi.org/10.1073/pnas.1120985109
Abstract
Dominant mutations or DNA amplification of tyrosine kinases are rare among the oncogenic alterations implicated in prostate cancer. We demonstrate that castration-resistant prostate cancer (CRPC) in men exhibits increased tyrosine phosphorylation, raising the question of whether enhanced tyrosine kinase activity is observed in prostate cancer in the absence of specific tyrosine kinase mutation or DNA amplification. We generated a mouse model of prostate cancer progression using commonly perturbed non-tyrosine kinase oncogenes and pathways and detected a significant up-regulation of tyrosine phosphorylation at the carcinoma stage. Phosphotyrosine peptide enrichment and quantitative mass spectrometry identified oncogene-specific tyrosine kinase signatures, including activation of EGFR, ephrin type-A receptor 2 (EPHA2), and JAK2. Kinase:substrate relationship analysis of the phosphopeptides also revealed ABL1 and SRC tyrosine kinase activation. The observation of elevated tyrosine kinase signaling in advanced prostate cancer and identification of specific tyrosine kinase pathways from genetically defined tumor models point to unique therapeutic approaches using tyrosine kinase inhibitors for advanced prostate cancer.This publication has 60 references indexed in Scilit:
- Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate CancerCancer Cell, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Activation of Aortic Endothelial Cells by Oxidized Phospholipids: A Phosphoproteomic AnalysisJournal of Proteome Research, 2010
- Eph receptors and ephrins in cancer: bidirectional signalling and beyondNature Reviews Cancer, 2010
- A chemical and phosphoproteomic characterization of dasatinib action in lung cancerNature Chemical Biology, 2010
- Translocations in epithelial cancersBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009
- Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostateNature Genetics, 2009
- Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinibThe Prostate, 2007
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylationProteomics, 2004